www.rinvoq.com Open in urlscan Pro
2600:9000:223e:2200:5:8ced:94c0:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Learn how AbbVie could help you save on RINVOQ.
Call 1-800-2RINVOQ or click to learn more >

Skip to Main content
 * Important Safety Information
 * Full Prescribing Information & Patient Information
    * Full Prescribing Information (English)
    * Medication Guide

 * Healthcare Professionals Site
 * View All Conditions

 * 1-800-2RINVOQ
 * Cost & Savings
 * Sign up for RINVOQ updates

 * 

 * About UC
    * What is UC?
    * Goals for UC Treatment
    * Choosing a UC Treatment

 * About RINVOQ
    * What is RINVOQ?
    * How RINVOQ Works
    * RINVOQ Results
    * Taking RINVOQ for UC
    * Patient Stories
    * Understanding Side Effects

 * Getting RINVOQ
    * Partner With a Gastroenterologist
    * Find a Gastroenterologist
    * UC Doctor Discussion Guide
    * UC Glossary

 * RINVOQ Resources
    * About RINVOQ Complete
    * Save on RINVOQ
    * Your Nurse Ambassador
    * RINVOQ Complete App
    * Preparing for RINVOQ
    * Insurance Explained
    * Building Your Routine

 * 1-800-2RINVOQ
 * Cost & Savings
 * Sign up for RINVOQ updates
 * View All Conditions
 * 

 * Important Safety Information
 * Full Prescribing Information & Patient Information
    * Full Prescribing Information (English)
    * Medication Guide

 * Healthcare Professionals Site
 * View All Conditions


IMPORTANT SAFETY INFORMATION & USE

Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots

For adults with moderate to severe ulcerative colitis (UC) in whom TNF blockers
did not work well



with RINVOQ, a once-daily pill

See the powerful results



RINVOQ FOR ULCERATIVE COLITIS


IN CLINICAL STUDIES, RINVOQ HELPED PEOPLE LIVING WITH UC EXPERIENCE REMISSION AT
8 WEEKS AND 1 YEAR, AND GET:

Rapid relief from UC symptoms* in as early as 2 weeks

*Based on the frequency of bowel movements and the amount of bloody stools.

No bowel urgency, no abdominal pain, and significantly reduced fatigue at 8
weeks

Steroid-free remission at 1 year

Visible colon lining repair † even at 1 year

†Areas that were visually assessed may not represent repair of the entire colon
lining.


GET HELPFUL INFO FROM ABBVIE

Have information sent to your inbox, plus receive our Put UC In Check card deck
with tips to help you take charge of your UC—free.

Sign up

SELECT IMPORTANT SAFETY INFORMATION

RINVOQ may cause serious side effects, including:

 * Serious Infections, Cancer and Immune System Problems, and Blood Clots.
 * Increased risk of death in people age 50+ with at least 1 heart disease risk
   factor.
 * Increased risk of major cardiovascular events, such as heart attack, stroke,
   or death in people age 50+ with at least 1 heart disease risk factor,
   especially in current or past smokers.
 * Serious allergic reactions. Do not take if allergic to RINVOQ or its
   ingredients.

Learn more about these and other serious side effects >

See full Important Safety Information below.

What’s the most important topic you want to discuss with your doctor about UC?

Staying up to date on UC treatments What I should be looking for in a treatment
Finding a treatment that's right for me

See the powerful results patients experienced with RINVOQ and discuss them at
your next appointment. View RINVOQ results >

Explore treatment options that can go beyond temporary symptom relief and
proactively support your long-term goals. Set UC treatment goals >

Ask your doctor about treatment options that offer lasting remission, even at 1
year. Set UC treatment goals >





HEAR FROM RINVOQ PATIENTS

See how real people put their UC in check with RINVOQ and achieved the results
they were looking for.

View patient videos


PARTNER UP WITH YOUR GASTROENTEROLOGIST

Your gastroenterologist is your partner in creating a treatment plan that aligns
with your long-term goals. Check out some of our strategies for making the most
of your appointment conversation.

Team up with your doctor


A ONCE-DAILY PILL

Make RINVOQ part of your routine.

Taking RINVOQ for UC




PERSONALIZED SUPPORT FROM THE START

Whether you need a hand navigating your insurance or have a question about your
condition, RINVOQ Complete is there to help you start and stay on track with
your prescribed RINVOQ treatment plan.

 

And with the RINVOQ Complete Savings Card, you may be eligible to pay as little
as $5 a month‡ for your prescription.

Discover RINVOQ Complete


INSPIRE OTHERS

Have you or a loved one been prescribed RINVOQ for UC? Share your experience to
help inform and inspire people like yourself. To participate, please email us
at info@SPEAKnetwork.net or call 855-465-8585.




USE

RINVOQ is a prescription medicine used to treat adults with moderate to severe
ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF)
blockers have been used, and did not work well or could not be tolerated. It is
not known if RINVOQ is safe and effective in children with ulcerative colitis.

IMPORTANT SAFETY INFORMATION


What is the most important information I should know about RINVOQ?

RINVOQ may cause serious side effects, including:

 * Serious infections. RINVOQ can lower your ability to fight infections.
   Serious infections have happened while taking RINVOQ, including tuberculosis
   (TB) and infections caused by bacteria, fungi, or viruses that can spread
   throughout the body. Some people have died from these infections. Your
   healthcare provider (HCP) should test you for TB before starting RINVOQ and
   check you closely for signs and symptoms of TB during treatment with RINVOQ.
   You should not start taking RINVOQ if you have any kind of infection unless
   your HCP tells you it is okay. If you get a serious infection, your HCP may
   stop your treatment until your infection is controlled. You may be at higher
   risk of developing shingles (herpes zoster).
 * Increased risk of death in people 50 years and older who have at least 1
   heart disease (cardiovascular) risk factor.
 * Cancer and immune system problems. RINVOQ may increase your risk of certain
   cancers. Lymphoma and other cancers, including skin cancers, can happen.
   Current or past smokers are at higher risk of certain cancers, including
   lymphoma and lung cancer. Follow your HCP's advice about having your skin
   checked for skin cancer during treatment with RINVOQ. Limit the amount of
   time you spend in sunlight. Wear protective clothing when you are in the sun
   and use sunscreen.
 * Increased risk of major cardiovascular (CV) events, such as heart attack,
   stroke, or death, in people 50 years and older who have at least 1 heart
   disease (CV) risk factor, especially if you are a current or past smoker.
 * Blood clots. Blood clots in the veins of the legs or lungs and arteries can
   happen with RINVOQ. This may be life-threatening and cause death. Blood clots
   in the veins of the legs and lungs have happened more often in people who are
   50 years and older and with at least 1 heart disease (CV) risk factor.
 * Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling
   faint or dizzy, or swelling of your lips, tongue, or throat, that may mean
   you are having an allergic reaction have been seen in people taking RINVOQ.
   Some of these reactions were serious. If any of these symptoms occur during
   treatment with RINVOQ, stop taking RINVOQ and get emergency medical help
   right away.
 * Tears in the stomach or intestines. This happens most often in people who
   take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get
   medical help right away if you get stomach-area pain, fever, chills, nausea,
   or vomiting.
 * Changes in certain laboratory tests. Your HCP should do blood tests before
   you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ
   treatment for a period of time if needed because of changes in these blood
   test results.

Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients
in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete
list of ingredients.

What should I tell my HCP BEFORE starting RINVOQ?

Tell your HCP if you:

 * Are being treated for an infection, have an infection that won't go away or
   keeps coming back, or have symptoms of an infection, such as:
   * - Fever, sweating, or chills
   * - Shortness of breath
   * - Warm, red, or painful skin or sores on your body
   * - Muscle aches
   * - Feeling tired
   * - Blood in phlegm
   * - Diarrhea or stomach pain
   * - Cough
   * - Weight loss
   * - Burning when urinating or urinating more often than normal
 * Have TB or have been in close contact with someone with TB.
 * Are a current or past smoker.
 * Have had a heart attack, other heart problems, or stroke.
 * Have or have had any type of cancer, hepatitis B or C, shingles (herpes
   zoster), blood clots in the veins of your legs or lungs, diverticulitis
   (inflammation in parts of the large intestine), or ulcers in your stomach or
   intestines.
 * Have other medical conditions, including liver problems, low blood cell
   counts, diabetes, chronic lung disease, HIV, or a weak immune system.
 * Live, have lived, or have traveled to parts of the country, such as the Ohio
   and Mississippi River valleys and the Southwest, that increase your risk of
   getting certain kinds of fungal infections. If you are unsure if you've been
   to these types of areas, ask your HCP.
 * Have recently received or are scheduled to receive a vaccine. People who take
   RINVOQ should not receive live vaccines.
 * Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may
   harm your unborn baby. Your HCP will check whether or not you are pregnant
   before you start RINVOQ. You should use effective birth control
   (contraception) to avoid becoming pregnant during treatment with RINVOQ and
   for 4 weeks after your last dose.
 * There is a pregnancy surveillance program for RINVOQ. The purpose of the
   program is to collect information about the health of you and your baby. If
   you become pregnant while taking RINVOQ, you are encouraged to report the
   pregnancy by calling 1-800-633-9110.
 * Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast
   milk. Do not breastfeed during treatment with RINVOQ and for 6 days after
   your last dose.

 

Tell your HCP about all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

 * Medicines for fungal or bacterial infections
 * Rifampicin or phenytoin
 * Medicines that affect your immune system

If you are not sure if you are taking any of these medicines, ask your HCP or
pharmacist.

What should I avoid while taking RINVOQ?

Avoid food or drink containing grapefruit during treatment with RINVOQ as it may
increase the risk of side effects.

What should I do or tell my HCP AFTER starting RINVOQ?

 * Tell your HCP right away if you have any symptoms of an infection. RINVOQ can
   make you more likely to get infections or make any infections you have worse.
 * Get emergency help right away if you have any symptoms of a heart attack or
   stroke while taking RINVOQ, including:
   * - Discomfort in the center of your chest that lasts for more than a few
     minutes or that goes away and comes back
   * - Severe tightness, pain, pressure, or heaviness in your chest, throat,
     neck, or jaw
   * - Pain or discomfort in your arms, back, neck, jaw, or stomach
   * - Shortness of breath with or without chest discomfort
   * - Breaking out in a cold sweat
   * - Nausea or vomiting
   * - Feeling lightheaded
   * - Weakness in one part or on one side of your body
   * - Slurred speech
 * Tell your HCP right away if you have any signs or symptoms of blood clots
   during treatment with RINVOQ, including:
   * - Swelling
   * - Pain or tenderness in one or both legs
   * - Sudden unexplained chest or upper back pain
   * - Shortness of breath or difficulty breathing
   *  
   *  
 * Tell your HCP right away if you have a fever or stomach-area pain that does
   not go away, and a change in your bowel habits.

What are other possible side effects of RINVOQ?

Common side effects include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus infections
(including cold sores), bronchitis, nausea, cough, fever, acne, headache,
increased blood levels of creatine phosphokinase, allergic reactions,
inflammation of hair follicles, stomach-area (abdominal) pain, increased weight,
flu, tiredness, lower number of certain types of white blood cells (neutropenia,
lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, increased liver enzyme levels, pneumonia, low number of red
blood cells (anemia), and infection of the stomach and intestine
(gastroenteritis).

A separation or tear to the lining of the back part of the eye (retinal
detachment) has happened in people with atopic dermatitis treated with RINVOQ.
Call your HCP right away if you have any sudden changes in your vision during
treatment with RINVOQ.

Some people taking RINVOQ may see medicine residue (a whole tablet or tablet
pieces) in their stool. If this happens, call your healthcare provider.

These are not all the possible side effects of RINVOQ.

How should I take RINVOQ?

RINVOQ is taken once a day with or without food. Do not split, crush, or chew
the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is
available in 15 mg, 30 mg, and 45 mg extended-release tablets.

This is the most important information to know about RINVOQ. For more
information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

USES

RINVOQ is a prescription medicine used to treat:

 * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more
   medicines called tumor necrosis factor (TNF) blockers have been used, and did
   not work well or could not be tolerated.
 * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called
   TNF blockers have been used, and did not work well or could not be tolerated.
 * Adults with active ankylosing spondylitis (AS) when 1 or more medicines
   called TNF blockers have been used, and did not work well or could not be
   tolerated.
 * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with
   objective signs of inflammation when a TNF blocker medicine has been used,
   and did not work well or could not be tolerated.
 * Adults with moderate to severe ulcerative colitis (UC) when 1 or more
   medicines called TNF blockers have been used, and did not work well or could
   not be tolerated.
 * Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines
   called TNF blockers have been used, and did not work well or could not be
   tolerated.

It is not known if RINVOQ is safe and effective in children with juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis,
non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's
disease.

 * Adults and children 12 years of age and older with moderate to severe eczema
   (atopic dermatitis [AD]) that did not respond to previous treatment and their
   eczema is not well controlled with other pills or injections, including
   biologic medicines, or the use of other pills or injections is not
   recommended.

RINVOQ is safe and effective in children 12 years of age and older weighing at
least 88 pounds (40 kg) with atopic dermatitis.

It is not known if RINVOQ is safe and effective in children under 12 years of
age with atopic dermatitis.

If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.

US-RNQ-220259

Please see the Full Prescribing Information, including the Medication Guide, for
RINVOQ.

Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have
any questions about AbbVie's RINVOQ.com website that have not been
answered, click here. This website and the information contained herein is
intended for use by US residents only, is provided for informational purposes
only and is not intended to replace a discussion with a healthcare provider. All
decisions regarding patient care must be made with a healthcare provider and
consider the unique characteristics of each patient.




RINVOQ (UPADACITINIB)

 * Moderate to Severe Ulcerative Colitis Home
 * RINVOQ Results
 * Partner With a Gastroenterologist
 * RINVOQ Complete
 * Cost & Savings
 * Sitemap

IMPORTANT INFORMATION FOR PATIENTS

 * Important Safety Information
 * Medication Guide
 * Full Prescribing Information (English)

INFORMATION FROM ABBVIE

 * Healthcare Professionals Site
 * COVID-19 Information
 * Accessibility Statement
 * Contact Us
 * Terms of Use
 * Privacy Notice
 * Cookies Settings
 * Your Privacy Choices

RINVOQ Complete Savings Card Terms and Conditions

‡Eligibility: Available to patients with commercial insurance coverage for
RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance
program is not available to patients receiving prescription reimbursement under
any federal, state, or government-funded insurance programs (for example,
Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE,
Department of Defense, or Veterans Affairs programs) or where prohibited by law.
Offer subject to change or termination without notice. Restrictions, including
monthly maximums, may apply. This is not health insurance. For full Terms and
Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional
information. To learn about AbbVie’s privacy practices and your privacy choices,
visit https://abbv.ie/corpprivacy.

US-RNQG-230183







TERMS AND CONDITIONS

AbbVie Inc. is providing this service to help patients find gastroenterologists
in their area who have experience with RINVOQ (upadacitinib).
 

No fees have been received by or paid to gastroenterologists for inclusion in
this specialist locator directory. Inclusion of a physician in this directory
does not represent an endorsement by or a recommendation from AbbVie Inc., nor
does it imply that the gastroenterologists on the list will determine that
RINVOQ is right for you.
 

You are ultimately responsible for the selection of a physician and it is an
important decision that you should consider carefully. This gastroenterologist
locator tool is just one source of information available to you. AbbVie Inc. is
the maker and marketer of RINVOQ (upadacitinib).


 

Close

US-RNQG-230183




LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-RNQG-230183




LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-RNQR-220513


US HEALTHCARE
PROFESSIONALS ONLY

You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.

I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.

Yes
No

US-RNQ-220010





LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-RNQ-220499


US HEALTHCARE
PROFESSIONALS ONLY

You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.

I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.

Yes
No

US-RNQ-220499


TERMS AND CONDITIONS

AbbVie Inc. is providing this service to help patients find rheumatologists in
their area who have experience with RINVOQ (upadacitinib).
 

No fees have been received by or paid to rheumatologists for inclusion in this
specialist locator directory. Inclusion of a physician in this directory does
not represent an endorsement by or a recommendation from AbbVie Inc., nor does
it imply that the rheumatologists on the list will determine that RINVOQ is
right for you.
 

You are ultimately responsible for the selection of a physician and it is an
important decision that you should consider carefully. This rheumatologist
locator tool is just one source of information available to you. AbbVie Inc. is
the maker and marketer of RINVOQ (upadacitinib).


 

Close

US-RNQR-210387

IMPORTANT SAFETY INFORMATION


What is the most important information I should know about RINVOQ?

RINVOQ may cause serious side effects, including:

 * Serious infections. RINVOQ can lower your ability to fight infections.
   Serious infections have happened while taking RINVOQ, including tuberculosis
   (TB) and infections caused by bacteria, fungi, or viruses that can spread
   throughout the body. Some people have died from these infections. Your
   healthcare provider (HCP) should test you for TB before starting RINVOQ and
   check you closely for signs and symptoms of TB during treatment with RINVOQ.
   You should not start taking RINVOQ if you have any kind of infection unless
   your HCP tells you it is okay. If you get a serious infection, your HCP may
   stop your treatment until your infection is controlled. You may be at higher
   risk of developing shingles (herpes zoster).
 * Increased risk of death in people 50 years and older who have at least 1
   heart disease (cardiovascular) risk factor.
 * Cancer and immune system problems. RINVOQ may increase your risk of certain
   cancers. Lymphoma and other cancers, including skin cancers, can happen.
   Current or past smokers are at higher risk of certain cancers, including
   lymphoma and lung cancer. Follow your HCP's advice about having your skin
   checked for skin cancer during treatment with RINVOQ. Limit the amount of
   time you spend in sunlight. Wear protective clothing when you are in the sun
   and use sunscreen.
 * Increased risk of major cardiovascular (CV) events, such as heart attack,
   stroke, or death, in people 50 years and older who have at least 1 heart
   disease (CV) risk factor, especially if you are a current or past smoker.
 * Blood clots. Blood clots in the veins of the legs or lungs and arteries can
   happen with RINVOQ. This may be life-threatening and cause death. Blood clots
   in the veins of the legs and lungs have happened more often in people who are
   50 years and older and with at least 1 heart disease (CV) risk factor.
 * Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling
   faint or dizzy, or swelling of your lips, tongue, or throat, that may mean
   you are having an allergic reaction have been seen in people taking RINVOQ.
   Some of these reactions were serious. If any of these symptoms occur during
   treatment with RINVOQ, stop taking RINVOQ and get emergency medical help
   right away.
 * Tears in the stomach or intestines. This happens most often in people who
   take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get
   medical help right away if you get stomach-area pain, fever, chills, nausea,
   or vomiting.
 * Changes in certain laboratory tests. Your HCP should do blood tests before
   you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ
   treatment for a period of time if needed because of changes in these blood
   test results.

Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients
in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete
list of ingredients.

What should I tell my HCP BEFORE starting RINVOQ?

Tell your HCP if you:

 * Are being treated for an infection, have an infection that won't go away or
   keeps coming back, or have symptoms of an infection, such as:
   * - Fever, sweating, or chills
   * - Shortness of breath
   * - Warm, red, or painful skin or sores on your body
   * - Muscle aches
   * - Feeling tired
   * - Blood in phlegm
   * - Diarrhea or stomach pain
   * - Cough
   * - Weight loss
   * - Burning when urinating or urinating more often than normal
 * Have TB or have been in close contact with someone with TB.
 * Are a current or past smoker.
 * Have had a heart attack, other heart problems, or stroke.
 * Have or have had any type of cancer, hepatitis B or C, shingles (herpes
   zoster), blood clots in the veins of your legs or lungs, diverticulitis
   (inflammation in parts of the large intestine), or ulcers in your stomach or
   intestines.
 * Have other medical conditions, including liver problems, low blood cell
   counts, diabetes, chronic lung disease, HIV, or a weak immune system.
 * Live, have lived, or have traveled to parts of the country, such as the Ohio
   and Mississippi River valleys and the Southwest, that increase your risk of
   getting certain kinds of fungal infections. If you are unsure if you've been
   to these types of areas, ask your HCP.
 * Have recently received or are scheduled to receive a vaccine. People who take
   RINVOQ should not receive live vaccines.
 * Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may
   harm your unborn baby. Your HCP will check whether or not you are pregnant
   before you start RINVOQ. You should use effective birth control
   (contraception) to avoid becoming pregnant during treatment with RINVOQ and
   for 4 weeks after your last dose.
 * There is a pregnancy surveillance program for RINVOQ. The purpose of the
   program is to collect information about the health of you and your baby. If
   you become pregnant while taking RINVOQ, you are encouraged to report the
   pregnancy by calling 1-800-633-9110.
 * Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast
   milk. Do not breastfeed during treatment with RINVOQ and for 6 days after
   your last dose.

 

Tell your HCP about all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

 * Medicines for fungal or bacterial infections
 * Rifampicin or phenytoin
 * Medicines that affect your immune system

If you are not sure if you are taking any of these medicines, ask your HCP or
pharmacist.

What should I avoid while taking RINVOQ?

Avoid food or drink containing grapefruit during treatment with RINVOQ as it may
increase the risk of side effects.

What should I do or tell my HCP AFTER starting RINVOQ?

 * Tell your HCP right away if you have any symptoms of an infection. RINVOQ can
   make you more likely to get infections or make any infections you have worse.
 * Get emergency help right away if you have any symptoms of a heart attack or
   stroke while taking RINVOQ, including:
   * - Discomfort in the center of your chest that lasts for more than a few
     minutes or that goes away and comes back
   * - Severe tightness, pain, pressure, or heaviness in your chest, throat,
     neck, or jaw
   * - Pain or discomfort in your arms, back, neck, jaw, or stomach
   * - Shortness of breath with or without chest discomfort
   * - Breaking out in a cold sweat
   * - Nausea or vomiting
   * - Feeling lightheaded
   * - Weakness in one part or on one side of your body
   * - Slurred speech
 * Tell your HCP right away if you have any signs or symptoms of blood clots
   during treatment with RINVOQ, including:
   * - Swelling
   * - Pain or tenderness in one or both legs
   * - Sudden unexplained chest or upper back pain
   * - Shortness of breath or difficulty breathing
   *  
   *  
 * Tell your HCP right away if you have a fever or stomach-area pain that does
   not go away, and a change in your bowel habits.

What are other possible side effects of RINVOQ?

Common side effects include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus infections
(including cold sores), bronchitis, nausea, cough, fever, acne, headache,
increased blood levels of creatine phosphokinase, allergic reactions,
inflammation of hair follicles, stomach-area (abdominal) pain, increased weight,
flu, tiredness, lower number of certain types of white blood cells (neutropenia,
lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, increased liver enzyme levels, pneumonia, low number of red
blood cells (anemia), and infection of the stomach and intestine
(gastroenteritis).

A separation or tear to the lining of the back part of the eye (retinal
detachment) has happened in people with atopic dermatitis treated with RINVOQ.
Call your HCP right away if you have any sudden changes in your vision during
treatment with RINVOQ.

Some people taking RINVOQ may see medicine residue (a whole tablet or tablet
pieces) in their stool. If this happens, call your healthcare provider.

These are not all the possible side effects of RINVOQ.

How should I take RINVOQ?

RINVOQ is taken once a day with or without food. Do not split, crush, or chew
the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is
available in 15 mg, 30 mg, and 45 mg extended-release tablets.

This is the most important information to know about RINVOQ. For more
information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

USES

RINVOQ is a prescription medicine used to treat:

 * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more
   medicines called tumor necrosis factor (TNF) blockers have been used, and did
   not work well or could not be tolerated.
 * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called
   TNF blockers have been used, and did not work well or could not be tolerated.
 * Adults with active ankylosing spondylitis (AS) when 1 or more medicines
   called TNF blockers have been used, and did not work well or could not be
   tolerated.
 * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with
   objective signs of inflammation when a TNF blocker medicine has been used,
   and did not work well or could not be tolerated.
 * Adults with moderate to severe ulcerative colitis (UC) when 1 or more
   medicines called TNF blockers have been used, and did not work well or could
   not be tolerated.
 * Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines
   called TNF blockers have been used, and did not work well or could not be
   tolerated.

It is not known if RINVOQ is safe and effective in children with juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis,
non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's
disease.

 * Adults and children 12 years of age and older with moderate to severe eczema
   (atopic dermatitis [AD]) that did not respond to previous treatment and their
   eczema is not well controlled with other pills or injections, including
   biologic medicines, or the use of other pills or injections is not
   recommended.

RINVOQ is safe and effective in children 12 years of age and older weighing at
least 88 pounds (40 kg) with atopic dermatitis.

It is not known if RINVOQ is safe and effective in children under 12 years of
age with atopic dermatitis.

If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.

US-RNQ-220259

Please see the Full Prescribing Information, including the Medication Guide, for
RINVOQ.

Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have
any questions about AbbVie's RINVOQ.com website that have not been
answered, click here. This website and the information contained herein is
intended for use by US residents only, is provided for informational purposes
only and is not intended to replace a discussion with a healthcare provider. All
decisions regarding patient care must be made with a healthcare provider and
consider the unique characteristics of each patient.


LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-RNQG-230183


LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

US-RNQR-190268


LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-RNQR-220513


YOU ARE NOW LEAVING THE RINVOQ WEBSITE

By clicking “Agree and continue” below, you acknowledge and agree that AbbVie
does not, in any way, endorse or recommend Doctor.com, the qualifications of any
physician associated with Doctor.com, or the quality of medical care any of
those physicians can provide. Please be aware that Doctor.com may have its own
set of terms and conditions and privacy policy for which AbbVie has no
responsibility. If you agree to the above, click “Agree and continue” to proceed
to Doctor.com. If you do not agree to the above, click “Cancel” to remain on
RINVOQ.com.

Agree and continue
Cancel

US-RNQR-220513


LEAVING ABBVIE WEB SITE

You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-RNQR-221299


US HEALTHCARE
PROFESSIONALS ONLY

You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.

I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.

Yes
No

US-RNQ-220010


US HEALTHCARE
PROFESSIONALS ONLY

You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.

I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.

Yes
No

US-RNQ-220010




IMPORTANT SAFETY INFORMATION & USE

Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots


IMPORTANT SAFETY INFORMATION & USE

Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots


IMPORTANT SAFETY INFORMATION & USE

Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots


IMPORTANT SAFETY INFORMATION & USE

Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots


USE

RINVOQ is a prescription medicine used to treat adults with moderate to severe
ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF)
blockers have been used, and did not work well or could not be tolerated. It is
not known if RINVOQ is safe and effective in children with ulcerative colitis.

IMPORTANT SAFETY INFORMATION


What is the most important information I should know about RINVOQ?

RINVOQ may cause serious side effects, including:

 * Serious infections. RINVOQ can lower your ability to fight infections.
   Serious infections have happened while taking RINVOQ, including tuberculosis
   (TB) and infections caused by bacteria, fungi, or viruses that can spread
   throughout the body. Some people have died from these infections. Your
   healthcare provider (HCP) should test you for TB before starting RINVOQ and
   check you closely for signs and symptoms of TB during treatment with RINVOQ.
   You should not start taking RINVOQ if you have any kind of infection unless
   your HCP tells you it is okay. If you get a serious infection, your HCP may
   stop your treatment until your infection is controlled. You may be at higher
   risk of developing shingles (herpes zoster).
 * Increased risk of death in people 50 years and older who have at least 1
   heart disease (cardiovascular) risk factor.
 * Cancer and immune system problems. RINVOQ may increase your risk of certain
   cancers. Lymphoma and other cancers, including skin cancers, can happen.
   Current or past smokers are at higher risk of certain cancers, including
   lymphoma and lung cancer. Follow your HCP's advice about having your skin
   checked for skin cancer during treatment with RINVOQ. Limit the amount of
   time you spend in sunlight. Wear protective clothing when you are in the sun
   and use sunscreen.
 * Increased risk of major cardiovascular (CV) events, such as heart attack,
   stroke, or death, in people 50 years and older who have at least 1 heart
   disease (CV) risk factor, especially if you are a current or past smoker.
 * Blood clots. Blood clots in the veins of the legs or lungs and arteries can
   happen with RINVOQ. This may be life-threatening and cause death. Blood clots
   in the veins of the legs and lungs have happened more often in people who are
   50 years and older and with at least 1 heart disease (CV) risk factor.
 * Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling
   faint or dizzy, or swelling of your lips, tongue, or throat, that may mean
   you are having an allergic reaction have been seen in people taking RINVOQ.
   Some of these reactions were serious. If any of these symptoms occur during
   treatment with RINVOQ, stop taking RINVOQ and get emergency medical help
   right away.
 * Tears in the stomach or intestines. This happens most often in people who
   take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get
   medical help right away if you get stomach-area pain, fever, chills, nausea,
   or vomiting.
 * Changes in certain laboratory tests. Your HCP should do blood tests before
   you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ
   treatment for a period of time if needed because of changes in these blood
   test results.

Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients
in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete
list of ingredients.

What should I tell my HCP BEFORE starting RINVOQ?

Tell your HCP if you:

 * Are being treated for an infection, have an infection that won't go away or
   keeps coming back, or have symptoms of an infection, such as:
   * - Fever, sweating, or chills
   * - Shortness of breath
   * - Warm, red, or painful skin or sores on your body
   * - Muscle aches
   * - Feeling tired
   * - Blood in phlegm
   * - Diarrhea or stomach pain
   * - Cough
   * - Weight loss
   * - Burning when urinating or urinating more often than normal
 * Have TB or have been in close contact with someone with TB.
 * Are a current or past smoker.
 * Have had a heart attack, other heart problems, or stroke.
 * Have or have had any type of cancer, hepatitis B or C, shingles (herpes
   zoster), blood clots in the veins of your legs or lungs, diverticulitis
   (inflammation in parts of the large intestine), or ulcers in your stomach or
   intestines.
 * Have other medical conditions, including liver problems, low blood cell
   counts, diabetes, chronic lung disease, HIV, or a weak immune system.
 * Live, have lived, or have traveled to parts of the country, such as the Ohio
   and Mississippi River valleys and the Southwest, that increase your risk of
   getting certain kinds of fungal infections. If you are unsure if you've been
   to these types of areas, ask your HCP.
 * Have recently received or are scheduled to receive a vaccine. People who take
   RINVOQ should not receive live vaccines.
 * Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may
   harm your unborn baby. Your HCP will check whether or not you are pregnant
   before you start RINVOQ. You should use effective birth control
   (contraception) to avoid becoming pregnant during treatment with RINVOQ and
   for 4 weeks after your last dose.
 * There is a pregnancy surveillance program for RINVOQ. The purpose of the
   program is to collect information about the health of you and your baby. If
   you become pregnant while taking RINVOQ, you are encouraged to report the
   pregnancy by calling 1-800-633-9110.
 * Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast
   milk. Do not breastfeed during treatment with RINVOQ and for 6 days after
   your last dose.

 

Tell your HCP about all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

 * Medicines for fungal or bacterial infections
 * Rifampicin or phenytoin
 * Medicines that affect your immune system

If you are not sure if you are taking any of these medicines, ask your HCP or
pharmacist.

What should I avoid while taking RINVOQ?

Avoid food or drink containing grapefruit during treatment with RINVOQ as it may
increase the risk of side effects.

What should I do or tell my HCP AFTER starting RINVOQ?

 * Tell your HCP right away if you have any symptoms of an infection. RINVOQ can
   make you more likely to get infections or make any infections you have worse.
 * Get emergency help right away if you have any symptoms of a heart attack or
   stroke while taking RINVOQ, including:
   * - Discomfort in the center of your chest that lasts for more than a few
     minutes or that goes away and comes back
   * - Severe tightness, pain, pressure, or heaviness in your chest, throat,
     neck, or jaw
   * - Pain or discomfort in your arms, back, neck, jaw, or stomach
   * - Shortness of breath with or without chest discomfort
   * - Breaking out in a cold sweat
   * - Nausea or vomiting
   * - Feeling lightheaded
   * - Weakness in one part or on one side of your body
   * - Slurred speech
 * Tell your HCP right away if you have any signs or symptoms of blood clots
   during treatment with RINVOQ, including:
   * - Swelling
   * - Pain or tenderness in one or both legs
   * - Sudden unexplained chest or upper back pain
   * - Shortness of breath or difficulty breathing
   *  
   *  
 * Tell your HCP right away if you have a fever or stomach-area pain that does
   not go away, and a change in your bowel habits.

What are other possible side effects of RINVOQ?

Common side effects include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus infections
(including cold sores), bronchitis, nausea, cough, fever, acne, headache,
increased blood levels of creatine phosphokinase, allergic reactions,
inflammation of hair follicles, stomach-area (abdominal) pain, increased weight,
flu, tiredness, lower number of certain types of white blood cells (neutropenia,
lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, increased liver enzyme levels, pneumonia, low number of red
blood cells (anemia), and infection of the stomach and intestine
(gastroenteritis).

A separation or tear to the lining of the back part of the eye (retinal
detachment) has happened in people with atopic dermatitis treated with RINVOQ.
Call your HCP right away if you have any sudden changes in your vision during
treatment with RINVOQ.

Some people taking RINVOQ may see medicine residue (a whole tablet or tablet
pieces) in their stool. If this happens, call your healthcare provider.

These are not all the possible side effects of RINVOQ.

How should I take RINVOQ?

RINVOQ is taken once a day with or without food. Do not split, crush, or chew
the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is
available in 15 mg, 30 mg, and 45 mg extended-release tablets.

This is the most important information to know about RINVOQ. For more
information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

USES

RINVOQ is a prescription medicine used to treat:

 * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more
   medicines called tumor necrosis factor (TNF) blockers have been used, and did
   not work well or could not be tolerated.
 * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called
   TNF blockers have been used, and did not work well or could not be tolerated.
 * Adults with active ankylosing spondylitis (AS) when 1 or more medicines
   called TNF blockers have been used, and did not work well or could not be
   tolerated.
 * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with
   objective signs of inflammation when a TNF blocker medicine has been used,
   and did not work well or could not be tolerated.
 * Adults with moderate to severe ulcerative colitis (UC) when 1 or more
   medicines called TNF blockers have been used, and did not work well or could
   not be tolerated.
 * Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines
   called TNF blockers have been used, and did not work well or could not be
   tolerated.

It is not known if RINVOQ is safe and effective in children with juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis,
non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's
disease.

 * Adults and children 12 years of age and older with moderate to severe eczema
   (atopic dermatitis [AD]) that did not respond to previous treatment and their
   eczema is not well controlled with other pills or injections, including
   biologic medicines, or the use of other pills or injections is not
   recommended.

RINVOQ is safe and effective in children 12 years of age and older weighing at
least 88 pounds (40 kg) with atopic dermatitis.

It is not known if RINVOQ is safe and effective in children under 12 years of
age with atopic dermatitis.

If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.

US-RNQ-220259

Please see the Full Prescribing Information, including the Medication Guide, for
RINVOQ.

Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have
any questions about AbbVie's RINVOQ.com website that have not been
answered, click here. This website and the information contained herein is
intended for use by US residents only, is provided for informational purposes
only and is not intended to replace a discussion with a healthcare provider. All
decisions regarding patient care must be made with a healthcare provider and
consider the unique characteristics of each patient.

AbbVie may use and disclose online usage data about you collected automatically
through online tracking technologies such as cookies, pixels, and web beacons
(collectively, “cookies”). We use this data for multiple purposes, including for
online targeted advertising (advertisements based on your interests inferred
from your activity across other unaffiliated sites and services) and website
analytics purposes, as well as to personalize content, save your preferences,
provide social media features, and track the site’s performance, as further
described in the"Cookies and similar tracking and data collection technologies"
section of our Privacy Notice. We retain this data for as long as necessary to
fulfill these purposes or as needed to comply with our record retention
obligations. We do not sell your data, but we may disclose it to our marketing
and advertising partners for purposes of online targeted advertising or for
website analytics purposes. To opt out of the use or disclosure of your
cookie-based personal data for online targeted advertising or for website
analytics purposes, or to otherwise manage your preferences, please click on
Cookie Settings below. For additional information on the categories of data we
collect, the purposes for their collection, disclosures to third parties, and
data retention, please visit ourPrivacy Notice.


Cookies Settings



PRIVACY PREFERENCE CENTER

You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.

Depending on the jurisdiction where you live, you may have the right to opt out
of the use and disclosure of your personal data for purposes of online targeted
advertising (advertisements based on your interests inferred from your activity
across other unaffiliated sites and services) or website analytics (to
understand website usage behavior and receive website analytics). To opt out of
the use and disclosure of your cookie-based personal data for these purposes,
you can toggle off “Functional” (for website analytics) and/or “Advertising”
(for online targeted advertising) below.

To opt out of the use and disclosure of your non-cookie-based information for
online targeted advertising purposes, please also click"Your Privacy Choices" on
our website.

Note that if we recognize your Global Privacy Control (GPC) as enabled, our
policy is to opt you out of the use or disclosure of your cookie-based personal
data for online targeted advertising and website analytics purposes for the
browser or device on which you have GPC enabled. However, unless you are logged
in to an AbbVie account that has the capability to link the personal data we
have about you to your browser or device, we cannot apply your GPC opt-out
request to your non-cookie based personal data because the connection between
your browser or device is not known to us. Thus, if you have GPC enabled, please
click"Your Privacy Choices" to opt out of the disclosure of your non-cookie
based personal data for these purposes.


MANAGE CONSENT PREFERENCES

REQUIRED COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.

View Vendor Details‎

FUNCTIONAL COOKIES

Functional Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.

View Vendor Details‎

ADVERTISING COOKIES

Advertising Cookies

These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.

View Vendor Details‎
Back Button


PERFORMANCE COOKIES



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

 * 
   
   View Cookies
   
    * Name
      cookie name

Confirm My Choices